Quick Answer
Bluejay Diagnostics, Inc. reported Operating Income Loss of -$6.95 million for the year ending 2025.
- Bluejay Diagnostics, Inc. showed an increase of +3.0% in Operating Income Loss from 2024 to 2025.
- This data is from Bluejay Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$148.2 thousand | Q1 2021: -$233.2 thousand | Q2 2021: -$666.1 thousand | Q3 2021: -$958.0 thousand | Q1 2022: -$2.07 million | Q2 2022: -$1.99 million | Q3 2022: -$2.81 million | Q1 2023: -$2.68 million | Q2 2023: -$2.90 million | Q3 2023: -$2.34 million | Q1 2024: -$2.43 million | Q2 2024: -$1.90 million | Q3 2024: -$1.36 million | Q1 2025: -$1.89 million | Q2 2025: -$1.99 million | Q3 2025: -$1.62 million.
- Over the full 6 years of available data (2020 to 2025), Bluejay Diagnostics, Inc.'s Operating Income Loss has declined by 481.2%.
- Historical annual values: Fiscal year 2025: -$6.95 million | Fiscal year 2024: -$7.17 million | Fiscal year 2023: -$10.31 million | Fiscal year 2022: -$9.32 million | Fiscal year 2021: -$3.23 million | Fiscal year 2020: -$1.20 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: